Numerous attempts have been made to modify tissue catecholamine levels by use of inhibitors of catecholamine biosynthesis. While several enzymatic steps are amenable to pharmacological control, recent interest has focused on inhibitors of tyrosine hydroxylase since this enzyme represents the rate-limiting step in norepinephrine biosynthesis.